Investigational Drug May Boost Survival in Men with Metastatic PCa

Share this content:

An investigational new agent called tasquinimod may help increase survival in men with metastatic prostate cancer

This oral agent has been found to extend progression-free survival by a mean of 7.6 months compared with 3.3 months for placebo.

John Schieszer has the latest on this new agent in today's Medical Minute.

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters